TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27708788

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Lorcaserin
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Combination of LLLT and lorcaserin
Number of subjects: 45

Group type: COMPARATOR
Intervention: LLLT
Number of subjects: 45
Study: 27708828

Group type: EXPERIMENTAL
Intervention: Shared decision-making (SDM) framework for care planning, implemented by trained professional caregivers in nursing homes.
Number of subjects: 0
Study: 27709460

Group type: EXPERIMENTAL
Intervention: Concurrent treatment with the proton pump inhibitor pantoprazole (DE-P)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Ingestion of dabigatran after a meal (DE-M)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Overall effectiveness using either strategy or a combination
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: DE-P (initial strategy)
Number of subjects: 117

Group type: COMPARATOR
Intervention: DE-M (initial strategy)
Number of subjects: 117
Study: 27710003

Group type: EXPERIMENTAL
Intervention: FORNET (forensic offender rehabilitation narrative exposure therapy)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Waiting list (control)
Number of subjects: 39
Study: 27710087

Group type: EXPERIMENTAL
Intervention: ProjectHeartforGirls.com web-based program
Number of subjects: 36
Study: 27711228

Group type: EXPERIMENTAL
Intervention: DNA/MVA Vaccination (GOVX-B11)
Number of subjects: 9
Study: 27712711

Group type: EXPERIMENTAL
Intervention: RESQ-7 (7-day recall)
Number of subjects: 446

Group type: COMPARATOR
Intervention: RESQ-eD (twice daily for 7 days)
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: RESQ-7
Number of subjects: 446

Group type: COMPARATOR
Intervention: RESQ-eD
Number of subjects: 446
Study: 27712741

Group type: EXPERIMENTAL
Intervention: Cardioband system
Number of subjects: 31
Study: 27712877

Group type: EXPERIMENTAL
Intervention: Phlebotomy with controlled hypovolemia
Number of subjects: 138

Group type: COMPARATOR
Intervention: No phlebotomy (control group)
Number of subjects: 138
Study: 27713075

Group type: EXPERIMENTAL
Intervention: Manual wheelchairs
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Power wheelchairs
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Income
Number of subjects: 421
Study: 27713637

Group type: EXPERIMENTAL
Intervention: Sunitinib at a starting dose of 50 mg/day on a 4-weeks-on/2-weeks-off schedule
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 348
Study: 27714595

Group type: EXPERIMENTAL
Intervention: Calcipotriol 50 µg/g and Betamethasone 0.5 mg/g aerosol foam
Number of subjects: 426

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 426
Study: 27714677

Group type: EXPERIMENTAL
Intervention: Rotavirus vaccination
Number of subjects: 0
Study: 27716119

Group type: EXPERIMENTAL
Intervention: Molecular prognostic test (GUCY2C)
Number of subjects: 41
Study: 27716131

Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography (CCTA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Myocardial perfusion scintigraphy (MPS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Integrated CCTA metric
Number of subjects: 0

Group type: COMPARATOR
Intervention: Integrated MPS measure
Number of subjects: 0
Study: 27716162

Group type: EXPERIMENTAL
Intervention: Enhanced cognitive behavioral therapy (CBT-E)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group without an eating disorder
Number of subjects: 0
Study: 27716218

Group type: EXPERIMENTAL
Intervention: Community-based football (one hour twice weekly for six months)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study: 27716244

Group type: EXPERIMENTAL
Intervention: HRP2 tests
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: pLDH test
Number of subjects: 424

Group type: COMPARATOR
Intervention: Blood smear microscopy (gold standard)
Number of subjects: 424
Study: 27716304

Group type: EXPERIMENTAL
Intervention: 20,000 IU vitamin D daily for 14 days followed by 10,000 IU per day for 7 days
Number of subjects: 91
Study: 27716344

Group type: EXPERIMENTAL
Intervention: SASHA
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ShMOLLI
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: MOLLI
Number of subjects: 40
Study: 27716343

Group type: EXPERIMENTAL
Intervention: Biomarkers of collagen remodeling (including degradation fragments of collagen type IV C6M)
Number of subjects: 1000
Study: 27716370

Group type: EXPERIMENTAL
Intervention: NIRS with a VOT (vascular occlusion test)
Number of subjects: 89
Study: 27716377

Group type: EXPERIMENTAL
Intervention: Urine biomarkers (cystatin C, NGAL, TIMP-2×IGFBP7) measured at admission and day 3
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Urine TIMP-2×IGFBP7 levels at admission
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Combination of clinical parameters and biomarker concentrations
Number of subjects: 195
Study: 27716402

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 27716819

Group type: EXPERIMENTAL
Intervention: Nintedanib (100, 150, and 200 mg orally twice daily) combined with low-dose cytarabine (20 mg subcutaneous injection twice daily for 10 days)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Nintedanib combined with low-dose cytarabine (LDAC)
Number of subjects: 13
Study: 27717372

Group type: EXPERIMENTAL
Intervention: VENTANA PD-L1 (SP263) Assay
Number of subjects: 181
Study: 27717384

Group type: EXPERIMENTAL
Intervention: Preoperative plasma GDF-15
Number of subjects: 1176

Group type: EXPERIMENTAL
Intervention: Logistic regression model including GDF-15
Number of subjects: 1176

Group type: COMPARATOR
Intervention: Cleveland-Clinic Acute Renal Failure (CC-ARF) score
Number of subjects: 1176
Study: 27717842

Group type: EXPERIMENTAL
Intervention: Adults with IBD
Number of subjects: 112

Group type: COMPARATOR
Intervention: Healthy individuals (controls)
Number of subjects: 112
Study: 27717861

Group type: EXPERIMENTAL
Intervention: Patients at risk of ARDS (Lung Injury Prediction Score of 4 or higher)
Number of subjects: 935

Group type: COMPARATOR
Intervention: Patients not at risk of ARDS
Number of subjects: 935
Study: 27718118

Group type: EXPERIMENTAL
Intervention: Telavancin (tested using revised broth microdilution method)
Number of subjects: 647
Study: 27719673

Group type: EXPERIMENTAL
Intervention: Knowledge of aetiology, diagnosis, and treatment of pre-eclampsia and eclampsia among health care providers.
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Awareness of magnesium sulphate for eclampsia management.
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Training and guidelines for management of pre-eclampsia.
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Referral practices for pre-eclampsia cases.
Number of subjects: 33
Study: 27719678

Group type: EXPERIMENTAL
Intervention: Community health workers' understanding of hypertension and seizures in pregnancy, including psychological explanations such as stress, tension, and fear.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Encouragement of rest, decreased salt intake, iron supplementation, and tetanus vaccination for hypertension management.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Administration of antihypertensives and MgSO by some staff nurses.
Number of subjects: 12
Study: 27719680

Group type: EXPERIMENTAL
Intervention: Task-sharing to Lady Health Workers (LHWs) for identification and management of pre-eclampsia
Number of subjects: 33

Group type: COMPARATOR
Intervention: Current LHW practices
Number of subjects: 33
Study: 27719681

Group type: EXPERIMENTAL
Intervention: Task-sharing among CHEWs for detection of early signs of pre-eclampsia
Number of subjects: 71
Study: 27720178

Group type: EXPERIMENTAL
Intervention: Plasma therapy
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 45

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Long-term follow-up
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Preemptive rituximab
Number of subjects: 45
Study: 27720278

Group type: EXPERIMENTAL
Intervention: Gray-scale analysis of carotid plaques (GSM, DWAs, black areas)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Presence of discrete white areas (DWAs) in ultrasound analysis
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Percent of plaque black area in any one component
Number of subjects: 38
Study: 27720417

Group type: EXPERIMENTAL
Intervention: Clinical weight loss maintenance (>10% weight loss)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Moderate maintenance (1-10% weight loss)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Weight regain
Number of subjects: 80
Study: 27720582

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938 plus vitamin D
Number of subjects: 0
Study: 27722750

Group type: EXPERIMENTAL
Intervention: FOLFIRI plus cetuximab
Number of subjects: 370

Group type: COMPARATOR
Intervention: FOLFIRI
Number of subjects: 370

Group type: COMPARATOR
Intervention: FOLFIRI plus bevacizumab
Number of subjects: 370
Study: 27722854

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg
Number of subjects: 19

Group type: COMPARATOR
Intervention: Simvastatin alone
Number of subjects: 19
Study: 27723665

Group type: EXPERIMENTAL
Intervention: Non-VKA oral anticoagulants (NOACs)
Number of subjects: 6273

Group type: COMPARATOR
Intervention: Vitamin K antagonists (VKAs)
Number of subjects: 6273

Group type: EXPERIMENTAL
Intervention: Oral anticoagulant (OAC) therapy
Number of subjects: 6273

Group type: EXPERIMENTAL
Intervention: CHA2DS2-VASc score
Number of subjects: 6273

Group type: EXPERIMENTAL
Intervention: HAS-BLED score
Number of subjects: 6273
Study: 27724844

Group type: EXPERIMENTAL
Intervention: Joint surgery
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: Back surgery
Number of subjects: 644

Group type: COMPARATOR
Intervention: Urological surgery
Number of subjects: 644
Study: 27724869

Group type: EXPERIMENTAL
Intervention: OCT plaque morphological assessment combined with FFR in group B (patients with TCFA)
Number of subjects: 3

Group type: COMPARATOR
Intervention: FFR negative lesions without TCFA in group A
Number of subjects: 3

Group type: COMPARATOR
Intervention: FFR-positive, PCI-treated intermediate lesions in group C
Number of subjects: 3
Study: 27724916

Group type: EXPERIMENTAL
Intervention: Robot-assisted therapy
Number of subjects: 77

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 77
Study: 27724918

Group type: EXPERIMENTAL
Intervention: Fistula repair surgery
Number of subjects: 364
Study: 27724970

Group type: EXPERIMENTAL
Intervention: 1 g of tranexamic acid (TxA) administered after the first blood sample was taken.
Number of subjects: 27
Study: 27725146

Group type: EXPERIMENTAL
Intervention: Intestinal microbiota signature for severe IBS
Number of subjects: 149

Group type: COMPARATOR
Intervention: Fecal and mucosal microbiota analysis
Number of subjects: 149
Study: 27725657

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitor (SSRI) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment (unmedicated)
Number of subjects: 0
Study: 27726853

Group type: EXPERIMENTAL
Intervention: Intensification of medical therapy (initiation of aspirin or initiation/increases in dose of ACE inhibitors, ARBs, statins, or β blockers)
Number of subjects: 185

Group type: COMPARATOR
Intervention: No intensification of medical therapy
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Mortality rate
Number of subjects: 185
Study: 27729265

Group type: EXPERIMENTAL
Intervention: Laser-assisted retrieval using excimer laser sheath technique
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Laser-assisted retrieval
Number of subjects: 251
Study: 27729313

Group type: EXPERIMENTAL
Intervention: Vemurafenib in combination with irinotecan and cetuximab
Number of subjects: 0
Study: 27729332

Group type: EXPERIMENTAL
Intervention: CTO PCI with scoring system for predicting complications
Number of subjects: 1569

Group type: EXPERIMENTAL
Intervention: CTO PCI with scoring system
Number of subjects: 1569
Study: 27729462

Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus (DM)
Number of subjects: 419

Group type: COMPARATOR
Intervention: Control group (non-DM)
Number of subjects: 419
Study: 27729766

Group type: EXPERIMENTAL
Intervention: 600 mg ALA
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 800 mg ALA
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 1,200 mg ALA
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Gastrointestinal prophylaxis medications
Number of subjects: 15
Study: 27729854

Group type: EXPERIMENTAL
Intervention: Accelerated Intermittent Theta Burst Stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham-Controlled
Number of subjects: 0
Study: 27730010

Group type: EXPERIMENTAL
Intervention: SAR422459 gene therapy
Number of subjects: 22
Study: 27730116

Group type: EXPERIMENTAL
Intervention: Genotyping with pharmacogenetic reports linked to decision support program
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Saliva sample collection and genotyping
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Use of decision support software
Number of subjects: 191
Study: 27730492

Group type: EXPERIMENTAL
Intervention: Clinical decision rule to assess severity in acute heart failure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical predictors available in the ED
Number of subjects: 0
Study: 27732627

Group type: EXPERIMENTAL
Intervention: High educational level (EL)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Middle educational level (EL)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Low educational level (EL)
Number of subjects: 185
Study: 27733070

Group type: EXPERIMENTAL
Intervention: Delayed-release dimethyl fumarate (DMF; 240 mg twice daily)
Number of subjects: 0
Study: 27733082

Group type: EXPERIMENTAL
Intervention: 4 week recall version of the UFS-QoL Questionnaire
Number of subjects: 271
Study: 27733159

Group type: EXPERIMENTAL
Intervention: Statin therapy (moderate-intensity)
Number of subjects: 564

Group type: COMPARATOR
Intervention: No statin therapy
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: HbA1c
Number of subjects: 564
Study: 27733243

Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg intravenously every 2 weeks until disease progression or treatment discontinuation
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 86
Study: 27733347

Group type: EXPERIMENTAL
Intervention: Computed tomographic angiography
Number of subjects: 10003

Group type: COMPARATOR
Intervention: Functional testing
Number of subjects: 10003
Study: 27733374

Group type: EXPERIMENTAL
Intervention: Cisplatin 30 mg/m² weekly with concurrent standard radiotherapy (60-66 Gy over 6-7 weeks) and panitumumab.
Number of subjects: 44
Study: 27733394

Group type: EXPERIMENTAL
Intervention: Vitamin D inadequacy (<50 nmol/L)
Number of subjects: 5664

Group type: EXPERIMENTAL
Intervention: Vitamin D concentration
Number of subjects: 5664
Study: 27733401

Group type: EXPERIMENTAL
Intervention: Reduced intake during the previous week
Number of subjects: 91245

Group type: EXPERIMENTAL
Intervention: Confinement to bed
Number of subjects: 91245

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 91245

Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 91245

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 91245

Group type: EXPERIMENTAL
Intervention: Low body mass index
Number of subjects: 91245
Study: 27733404

Group type: EXPERIMENTAL
Intervention: Highest quartile of ultraprocessed food consumption
Number of subjects: 8451

Group type: COMPARATOR
Intervention: Lowest quartile of ultraprocessed food consumption
Number of subjects: 8451
Study: 27733407

Group type: EXPERIMENTAL
Intervention: Vegetable, fruit, and white rice dietary pattern (VFR)
Number of subjects: 923
Study: 27733412

Group type: EXPERIMENTAL
Intervention: HBV/HCV dual infection
Number of subjects: 997

Group type: COMPARATOR
Intervention: HCV monoinfection
Number of subjects: 997
Study: 27733413

Group type: EXPERIMENTAL
Intervention: Early oral glucose tolerance test (OGTT) 75 g
Number of subjects: 748

Group type: EXPERIMENTAL
Intervention: Glycosylated fibronectin (glyFn)
Number of subjects: 748

Group type: EXPERIMENTAL
Intervention: New screening algorithm based on multivariable risk estimation using early OGTT 75 g and/or glyFn results
Number of subjects: 748
Study: 27733431

Group type: EXPERIMENTAL
Intervention: 18F-fluoride PET-CT with contrast-enhanced ECG-gated imaging
Number of subjects: 15

Group type: COMPARATOR
Intervention: Nongated PET and noncontrast CT
Number of subjects: 15
Study: 27733495

Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 0
Study: 27733826

Group type: EXPERIMENTAL
Intervention: Structured Mirrors Intervention
Number of subjects: 0
Study: 27733954

Group type: EXPERIMENTAL
Intervention: Positive psychology intervention (telephone-based, 12-week duration)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Positive psychology intervention
Number of subjects: 15
Study: 27734949

Group type: EXPERIMENTAL
Intervention: Cystinosis patients homozygous for the 57-kb deletion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched healthy controls
Number of subjects: 0
Study: 27736293

Group type: EXPERIMENTAL
Intervention: PHiD-CV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PHiD-CV (additional dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (unvaccinated against Streptococcus pneumoniae)
Number of subjects: 0
Study: 27736729

Group type: EXPERIMENTAL
Intervention: KB004 (anti-EphA3 monoclonal antibody) administered by intravenous infusion on days 1, 8, and 15 of each 21-day cycle in escalating doses.
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: KB004 (anti-EphA3 monoclonal antibody) administered by intravenous infusion.
Number of subjects: 64
Study: 27737683

Group type: EXPERIMENTAL
Intervention: Hypothermia (body temperature below 36 °C)
Number of subjects: 525
Study: 27737957

Group type: EXPERIMENTAL
Intervention: Treated hypertension
Number of subjects: 2604

Group type: EXPERIMENTAL
Intervention: Untreated hypertension
Number of subjects: 2604
Study: 27738789

Group type: EXPERIMENTAL
Intervention: 9-cycle VMP schedule (4 cycles of twice weekly bortezomib) from VISTA trial
Number of subjects: 113

Group type: COMPARATOR
Intervention: 6-cycle VMP schedule (1 cycle of twice weekly and 5 cycles of weekly bortezomib, then bortezomib-based maintenance) from PETHEMA/GEM05 trial
Number of subjects: 113
Study: 27738920

Group type: EXPERIMENTAL
Intervention: ACEIs/ARBs
Number of subjects: 926

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 926

Group type: EXPERIMENTAL
Intervention: BBs
Number of subjects: 926

Group type: EXPERIMENTAL
Intervention: PPIs
Number of subjects: 926

Group type: EXPERIMENTAL
Intervention: Optimal Medical Therapy (OMT)
Number of subjects: 926
Study: 27739003

Group type: EXPERIMENTAL
Intervention: Two second-generation trabecular micro-bypass stents
Number of subjects: 57
Study: 27739935

Group type: EXPERIMENTAL
Intervention: Class one (38% of participants) reported elevated needs in multiple areas.
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Class two (23% of participants) reported low needs.
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Class three (40% of participants) reported substance use and psychological needs.
Number of subjects: 353
Study: 27739944

Group type: EXPERIMENTAL
Intervention: Pipeline Embolization Device (PED)
Number of subjects: 107
Study: 27740536

Group type: EXPERIMENTAL
Intervention: Raltegravir-based regimen (with emtricitabine/tenofovir)
Number of subjects: 39
Study: 27740633

Group type: EXPERIMENTAL
Intervention: Epigenetic therapy (decitabine and panobinostat)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Ultrasensitive sequencing approach
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Serial sequencing of bone marrow samples
Number of subjects: 25
Study: 27741031

Group type: EXPERIMENTAL
Intervention: Hybrid testing approach (census, multidisease community health campaigns, home-based testing)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) CD4 testing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multidisease testing at CHCs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community mobilization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hybrid testing approach
Number of subjects: 0
Study: 27741195

Group type: EXPERIMENTAL
Intervention: Copper intrauterine devices (20% of participants)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Levonorgestrel intrauterine devices (46% of participants)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Contraceptive implants (34% of participants)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Overall LARC users
Number of subjects: 200
Study: 27742086

Group type: EXPERIMENTAL
Intervention: Icatibant (part of the Icatibant Outcome Survey)
Number of subjects: 418
Study: 27742126

Group type: EXPERIMENTAL
Intervention: Fasting duration (0 to 5 hours)
Number of subjects: 2713
Study: 27742581

Group type: EXPERIMENTAL
Intervention: n-3 PUFA (1.9g/day for 12 weeks)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 27742908

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (AA), 1,000 mg daily, and prednisone (P), 5 mg twice daily
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate plus prednisone (AA+P)
Number of subjects: 11
Study: 27743353

Group type: EXPERIMENTAL
Intervention: Biosimilar filgrastim (Nivestim™) as primary prophylaxis
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Biosimilar filgrastim (Nivestim™) as secondary prophylaxis
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Biosimilar filgrastim (Nivestim™)
Number of subjects: 386
Study: 27743502

Group type: EXPERIMENTAL
Intervention: Obeticholic acid (OCA)
Number of subjects: 0
Study: 27743728

Group type: EXPERIMENTAL
Intervention: Ultrasound elastography
Number of subjects: 45
Study: 27743860

Group type: EXPERIMENTAL
Intervention: Reasons for purchasing prepackaged, processed meals
Number of subjects: 160
Study: 27743953

Group type: EXPERIMENTAL
Intervention: FFR derived from coronary computed tomography angiography (CTA)
Number of subjects: 60
Study: 27744037

Group type: EXPERIMENTAL
Intervention: Gemcitabine combined with microbubbles under sonication
Number of subjects: 10